Scandinavian Biopharma recruits Agneta Lissmats as Senior Director Biostatistics

Scandinavian Biopharma is now strengthening its organisation by recruiting Agneta Lissmats as Senior Director Biostatistics. The company is in late-stage clinical development and has an ambitious development program with several ongoing clinical studies for the ETEC vaccine candidate ETVAX®. Agneta has extensive experience in clinical drug development and has held similar positions at pharmaceutical companies such as Oncopeptides and Sobi.

– In my role as a biostatistician, I provide statistical and scientific support to clinical and regulatory strategies. I hope that my knowledge and experience will help the company make informed decisions for the development of the world’s first ETEC vaccine, says Agneta Lissmats.

– Clinical trials are complex and clinical development work is enormously costly and time-consuming, so it is very important that studies are well designed. Agneta’s long experience as a biostatistician will come in handy as we prepare our Phase III trials of our ETEC vaccine, says Björn Sjöstrand, CEO of Scandinavian Biopharma.



Go to MyNewsdesk

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.